Mladenovska, Kristina
Preferred name
Mladenovska, Kristina
Official Name
Mladenovska, Kristina
Main Affiliation
Email
kristina.mladenovska@ff.ukim.edu.mk
53 results
Now showing 1 - 10 of 53
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Anti-inflammatory properties of L. casei loaded whey protein-alginate microparticles in animal model of colitis(2014) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Histopathological and immunohistochemical examibation on the colon of rats with TNBS-induced colitis after administration of functional food containing microencapsulated synbiotic(2016); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, [(3-Chlorobenzamido)methyl]triethylammonium Chloride(MDPI AG, 2015-04-01); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a): A Single-Center Study(aop.sagepub.com, 2016); ; ; Domazetovska, SaskaBackground: There are little evidences about the therapeutic efficacy of different lipid-lowering agents in the reduction of elevated lipoprotein(a) [Lp(a)]. Objective: testing the effect of different lipid-lowering agents on elevated Lp(a). Methods: prospective interventional study performed in patients with CAD, or high CAD risk, with Lp(a), >50 mg/dL. Lp(a), total cholesterol (C), HDL-C, LDL-C, triglycerides (TGs), apolipoprotein (Apo) A1, Apo B, enzymes of myocyte and hepatic injury were comparatively analyzed between 4 lipid-lowering strategies: rosuvastatin (R group) 40 mg, atorvastatin (A group) 80 mg, atorvastatin 40 mg add-on micronized fenofibrate (A+F group), and atorvastatin 40 mg add-on 1 g extended-release niacin (A+ERN group). Comparison was made for their therapeutic efficacy on Lp(a), and safety. Results: 87 patients with mean Lp(a) 94.6 ± 39.6 mg/dL were analyzed. Groups: 25 patients in the R, 22 in the A, 20 in the A+F and 20 in A+ERN group. Significant reduction in all lipid fractions in all treatment groups was reported after 6 months. The average reduction of Lp(a) was 15.9 ± 21.0 mg/dL, with: 18.2 ± 24.8 (P = 0.001) in the R group, 17.3 ± 10.4 (P = 0.001) in A+F, 19.5 ± 10.9 (P = 0.001) in A+ERN and the lowest in the A group (11.24 ± 22.91, P = 0.032). No adverse effects were observed in any of the treatment groups. Conclusions: When compared with atorvastatin, it seems that rosuvastatin can achieve more significant decrease of Lp(a).The efficacy of the second one can be increased by adding fibrate or ERN. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Lactobacillus casei Encapsulated in Soy Protein Isolate and Alginate Microparticles Prepared by Spray Drying(Faculty of Food Technology and Biotechnology - University of Zagreb, 2017-06); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Dietetic approach in patients with irritable bowel syndrome – a case report(Macedonian Pharmaceutical Association, 2020-10-29) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles(2007); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pathological changes of colon in the TNBS model of colitis in rats treated by functional food containing probiotic/synbiotic formulation(2014) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Nutritional management of chronic kidney disease – a case report(Macedonian Pharmaceutical Association, 2020-10-29) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Nutrition in COPD patients - case study(Macedonian Pharmaceutical Association, 2020-10-29);